REGIMENTED PHOSPHODIESTERASE TYPE 5 INHIBITOR USE REDUCES EMERGENCY DEPARTMENT VISITS FOR RECURRENT ISCHEMIC PRIAPISM

被引：0
|
作者：
Hou, L. [1 ]
Burnett, A. [1 ]
机构：
[1] Johns Hopkins Univ, Sch Med, Baltimore, MD 21218 USA
来源：
JOURNAL OF SEXUAL MEDICINE | 2021年 / 18卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
122
引用
收藏
页码：S64 / S65
页数：4
相关论文
共 50 条
  • [21] PHOSPHODIESTERASE TYPE-5 INHIBITOR USE IN TYPE 2 DIABETES IS ASSOCIATED WITH A REDUCTION IN ALL CAUSE MORTALITY
    Heald, A.
    Hackett, G.
    Hutchings, D.
    Hackett, G.
    JOURNAL OF SEXUAL MEDICINE, 2015, 12 : 192 - 193
  • [22] Sildenafil, a phosphodiesterase type 5 inhibitor, reduces antidepressant-like activity of paroxetine in the forced swim test in mice
    Katarzyna Socała
    Dorota Nieoczym
    Elżbieta Wyska
    Ewa Poleszak
    Piotr Właź
    Pharmacological Reports, 2012, 64 : 1259 - 1266
  • [23] Sildenafil, a phosphodiesterase type 5 inhibitor, reduces antidepressant-like activity of paroxetine in the forced swim test in mice
    Socala, Katarzyna
    Nieoczym, Dorota
    Wyska, Elzbieta
    Poleszak, Ewa
    Wlaz, Piotr
    PHARMACOLOGICAL REPORTS, 2012, 64 (05) : 1259 - 1266
  • [24] Long-term phosphodiesterase type 5 inhibitor therapy reduces priapic activity in transgenic sickle cell mice
    Bivalacqua, TJ
    Champion, HC
    Mason, W
    Burnett, AL
    JOURNAL OF UROLOGY, 2006, 175 (04): : 387 - 387
  • [25] Phosphodiesterase Type-5 Inhibitor Use in Type 2 Diabetes Is Associated with a Reduction in All-Cause Mortality
    Anderson, Simon G.
    Hutchings, David C.
    Trafford, Andrew W.
    Heald, Adrian H.
    DIABETES, 2015, 64 : A412 - A412
  • [26] Phosphodiesterase type-5 inhibitor use in type 2 diabetes is associated with a reduction in all-cause mortality
    Anderson, Simon G.
    Hutchings, David C.
    Woodward, Mark
    Rahimi, Kazem
    Rutter, Martin K.
    Kirby, Mike
    Hackett, Geoff
    Trafford, Andrew W.
    Heald, Adrian H.
    HEART, 2016, 102 (21) : 1750 - 1756
  • [27] Phosphodiesterase Type 5 Inhibitor Use Following Radical Prostatectomy is not Associated with an Increased Risk of Biochemical Recurrence
    Jo, Jung Ki
    Kim, Kwangmo
    Lee, Sang Eun
    Lee, Jung Keun
    Byun, Seok-Soo
    Hong, Sung Kyu
    ANNALS OF SURGICAL ONCOLOGY, 2016, 23 (05) : 1760 - 1767
  • [28] Phosphodiesterase type 5 inhibitor use among pregnant and reproductive-age women in the United States
    Liu, Wei
    Menzin, Talia J.
    Woods, Corinne M.
    Haug, Nicole R.
    Li, Jie
    Mathew, Justin A.
    Nguyen, Christine P.
    Chai, Grace P.
    Moeny, David G.
    Shinde, Mayura
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 (02) : 126 - 134
  • [29] PHOSPHODIESTERASE TYPE 5 INHIBITOR USE IS NOT ASSOCIATED WITH BIOCHEMICAL RECURRENCE AFTER DEFINITIVE THERAPY FOR PROSTATE CANCER
    Leapman, Michael
    Nguyen, Hao
    Cowan, Janet
    Porten, Sima
    Meng, Maxwell
    Cooperberg, Matthew
    Carroll, Peter
    JOURNAL OF UROLOGY, 2016, 195 (04): : E1043 - E1043
  • [30] Phosphodiesterase Type 5 Inhibitor Use Following Radical Prostatectomy is not Associated with an Increased Risk of Biochemical Recurrence
    Jung Ki Jo
    Kwangmo Kim
    Sang Eun Lee
    Jung Keun Lee
    Seok-Soo Byun
    Sung Kyu Hong
    Annals of Surgical Oncology, 2016, 23 : 1760 - 1767
12345